145 related articles for article (PubMed ID: 27689099)
1. Rotavirus Recombinant VP6 Nanotubes Act as an Immunomodulator and Delivery Vehicle for Norovirus Virus-Like Particles.
Malm M; Tamminen K; Lappalainen S; Vesikari T; Blazevic V
J Immunol Res; 2016; 2016():9171632. PubMed ID: 27689099
[TBL] [Abstract][Full Text] [Related]
2. Rotavirus capsid VP6 tubular and spherical nanostructures act as local adjuvants when co-delivered with norovirus VLPs.
Malm M; Heinimäki S; Vesikari T; Blazevic V
Clin Exp Immunol; 2017 Sep; 189(3):331-341. PubMed ID: 28407442
[TBL] [Abstract][Full Text] [Related]
3. Rotavirus VP6 Adjuvant Effect on Norovirus GII.4 Virus-Like Particle Uptake and Presentation by Bone Marrow-Derived Dendritic Cells In Vitro and In Vivo.
Tamminen K; Heinimäki S; Vesikari T; Blazevic V
J Immunol Res; 2020; 2020():3194704. PubMed ID: 32411793
[TBL] [Abstract][Full Text] [Related]
4. Internalization and antigen presentation by mouse dendritic cells of rotavirus VP6 preparations differing in nanostructure.
Tamminen K; Heinimäki S; Gröhn S; Blazevic V
Mol Immunol; 2020 Jul; 123():26-31. PubMed ID: 32388275
[TBL] [Abstract][Full Text] [Related]
5. Rotavirus VP6 as an Adjuvant for Bivalent Norovirus Vaccine Produced in
Malm M; Diessner A; Tamminen K; Liebscher M; Vesikari T; Blazevic V
Pharmaceutics; 2019 May; 11(5):. PubMed ID: 31083495
[TBL] [Abstract][Full Text] [Related]
6. Understanding internalization of rotavirus VP6 nanotubes by cells: towards a recombinant vaccine.
Rodríguez M; Wood C; Sanchez-López R; Castro-Acosta RM; Ramírez OT; Palomares LA
Arch Virol; 2014 May; 159(5):1005-15. PubMed ID: 24232915
[TBL] [Abstract][Full Text] [Related]
7. Immune responses elicited against rotavirus middle layer protein VP6 inhibit viral replication in vitro and in vivo.
Lappalainen S; Pastor AR; Tamminen K; López-Guerrero V; Esquivel-Guadarrama F; Palomares LA; Vesikari T; Blazevic V
Hum Vaccin Immunother; 2014; 10(7):2039-47. PubMed ID: 25424814
[TBL] [Abstract][Full Text] [Related]
8. Targeting of rotavirus VP6 to DEC-205 induces protection against the infection in mice.
Badillo-Godinez O; Gutierrez-Xicotencatl L; Plett-Torres T; Pedroza-Saavedra A; Gonzalez-Jaimes A; Chihu-Amparan L; Maldonado-Gama M; Espino-Solis G; Bonifaz LC; Esquivel-Guadarrama F
Vaccine; 2015 Aug; 33(35):4228-37. PubMed ID: 25850020
[TBL] [Abstract][Full Text] [Related]
9. Rotavirus Inner Capsid VP6 Acts as an Adjuvant in Formulations with Particulate Antigens Only.
Heinimäki S; Tamminen K; Hytönen VP; Malm M; Blazevic V
Vaccines (Basel); 2020 Jul; 8(3):. PubMed ID: 32645976
[TBL] [Abstract][Full Text] [Related]
10. Improved characteristics and protective efficacy in an animal model of E. coli-derived recombinant double-layered rotavirus virus-like particles.
Li T; Lin H; Zhang Y; Li M; Wang D; Che Y; Zhu Y; Li S; Zhang J; Ge S; Zhao Q; Xia N
Vaccine; 2014 Apr; 32(17):1921-31. PubMed ID: 24530406
[TBL] [Abstract][Full Text] [Related]
11. Protection against live rotavirus challenge in mice induced by parenteral and mucosal delivery of VP6 subunit rotavirus vaccine.
Lappalainen S; Pastor AR; Malm M; López-Guerrero V; Esquivel-Guadarrama F; Palomares LA; Vesikari T; Blazevic V
Arch Virol; 2015 Aug; 160(8):2075-8. PubMed ID: 26016444
[TBL] [Abstract][Full Text] [Related]
12. CD40 is necessary for activation of naïve T cells by a dendritic cell line in vivo but not in vitro.
Haase C; Michelsen BK; Jørgensen TN
Scand J Immunol; 2004 Mar; 59(3):237-45. PubMed ID: 15030573
[TBL] [Abstract][Full Text] [Related]
13. The assembly conformation of rotavirus VP6 determines its protective efficacy against rotavirus challenge in mice.
Pastor AR; Rodríguez-Limas WA; Contreras MA; Esquivel E; Esquivel-Guadarrama F; Ramírez OT; Palomares LA
Vaccine; 2014 May; 32(24):2874-7. PubMed ID: 24583002
[TBL] [Abstract][Full Text] [Related]
14. Nonreplicating recombinant vaccinia virus expressing CD40 ligand enhances APC capacity to stimulate specific CD4+ and CD8+ T cell responses.
Feder-Mengus C; Schultz-Thater E; Oertli D; Marti WR; Heberer M; Spagnoli GC; Zajac P
Hum Gene Ther; 2005 Mar; 16(3):348-60. PubMed ID: 15812230
[TBL] [Abstract][Full Text] [Related]
15. Particle bombardment-mediated DNA vaccination with rotavirus VP6 induces high levels of serum rotavirus IgG but fails to protect mice against challenge.
Choi AH; Knowlton DR; McNeal MM; Ward RL
Virology; 1997 May; 232(1):129-38. PubMed ID: 9185596
[TBL] [Abstract][Full Text] [Related]
16. Norovirus VLPs and rotavirus VP6 protein as combined vaccine for childhood gastroenteritis.
Blazevic V; Lappalainen S; Nurminen K; Huhti L; Vesikari T
Vaccine; 2011 Oct; 29(45):8126-33. PubMed ID: 21854823
[TBL] [Abstract][Full Text] [Related]
17. Bone marrow dendritic cells internalize live RF-81 bovine rotavirus and rotavirus-like particles (RF 2/6-GFP-VLP and RF 8*2/6/7-VLP) but are only activated by live bovine rotavirus.
Istrate C; Douagi I; Charpilienne A; McInerney GM; Hidmark A; Johansen K; Larsson M; Magnusson KE; Poncet D; Svensson L; Hinkula J
Scand J Immunol; 2007 Jun; 65(6):494-502. PubMed ID: 17523941
[TBL] [Abstract][Full Text] [Related]
18. Triple layered rotavirus VLP production: kinetics of vector replication, mRNA stability and recombinant protein production.
Vieira HL; Estêvão C; Roldão A; Peixoto CC; Sousa MF; Cruz PE; Carrondo MJ; Alves PM
J Biotechnol; 2005 Oct; 120(1):72-82. PubMed ID: 16023241
[TBL] [Abstract][Full Text] [Related]
19. The VP6 protein of rotavirus interacts with a large fraction of human naive B cells via surface immunoglobulins.
Parez N; Garbarg-Chenon A; Fourgeux C; Le Deist F; Servant-Delmas A; Charpilienne A; Cohen J; Schwartz-Cornil I
J Virol; 2004 Nov; 78(22):12489-96. PubMed ID: 15507636
[TBL] [Abstract][Full Text] [Related]
20. Molecular epidemiology of rotavirus and norovirus in Ile-Ife, Nigeria: high prevalence of G12P[8] rotavirus strains and detection of a rare norovirus genotype.
Oluwatoyin Japhet M; Adeyemi Adesina O; Famurewa O; Svensson L; Nordgren J
J Med Virol; 2012 Sep; 84(9):1489-96. PubMed ID: 22825829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
